ExpansionApr 29, 2026, 04:50 PM
CTXR Subsidiary Citius Oncology Ships LYMPHIR to Europe
AI Summary
Citius Pharmaceuticals, Inc.'s majority-owned subsidiary, Citius Oncology, Inc. (CTOR), announced the initial shipment of LYMPHIR (denileukin diftitox-cxdl) to Europe. This strategic move expands international patient access through regional distribution partners and Named Patient Programs, complementing the ongoing U.S. commercial launch. LYMPHIR was approved by the U.S. FDA in August 2024 and launched in the U.S. in December 2025 for relapsed or refractory CTCL, with an estimated initial U.S. market exceeding $400 million.
Key Highlights
- Citius Oncology, a CTXR subsidiary, shipped the initial order of LYMPHIR to Europe via a regional distribution partner.
- LYMPHIR will be available to eligible patients through Named Patient Programs in specific international markets.
- This marks a strategic step to expand international patient access to LYMPHIR beyond the United States.
- The European distribution complements the ongoing U.S. commercial launch strategy for LYMPHIR .
- LYMPHIR was approved by the U.S. FDA in August 2024 and launched in the U.S. in December 2025.
- The estimated initial U.S. market for LYMPHIR currently exceeds $400 million.
- Citius acquired exclusive license rights for LYMPHIR in 2021 for all markets except India, Japan, and parts of Asia.